1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Gottlieb Sees Opportunity For Pharma To Seek Continuity Of COVID-19 Trial Accommodations

 
• By Anju Ghangurde

Decentralized and remote flexibilities should stay, Gottlieb says, but so should e-detailing efforts.

FDA commissioner Scott Gottlieb

Pharma could demonstrate the collective benefits of COVID-19-related accommodations for clinical trials permitted by US Food and Drug Administration and potentially seek to make some of these adjustments “more permanent,” former US FDA Commissioner Scott Gottlieb said.

Addressing the Indegene Digital Summit 2020, Gottlieb indicated that while some of the changes made by the agency were accommodations for COVID-19, the reality is that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

US FDA Rare Disease Case Studies Provide Development Models For Sponsors

 
• By Laura Helbling

Sanofi’s Xenpozyme and Sentynyl’s Nulibry are the first two case studies the FDA is using to continue educating rare disease sponsors on best practices.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

More from R&D